Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis

Biomarkers in Medicine

Volumn 8, Issue 5, 2014, Pages 653-661

  Sáenz Cuesta, Matías ^a,b   Irizar, Haritz ^a,b   Castillo Triviño, Tamara ^a,b   Muñoz Culla, Maider ^a,b   Osorio Querejeta, Iñaki ^a,b   Prada, Alvaro ^a,b   Sepúlveda, Lucía ^a,b   López Mato, María P ^c   De Munain, Adolfo López ^a,b,d,e   Comabella, Manuel ^b,f   Villar, Luisa M ^b,g   Olascoaga, Javier ^a,b   Otaegui, David ^a,b  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c Basque Government   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

extracellular vesicles; microparticles; multiple sclerosis; secondary progressive; treatment

Indexed keywords

BETA1A INTERFERON; BETA3 INTEGRIN; CD14 ANTIGEN; CD45 ANTIGEN; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE MICROPARTICLE; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; MONOCYTE MICROPARTICLE; MULTIPLE SCLEROSIS; PLATELET MICROPARTICLE; RELAPSE; BLOOD; BLOOD CELL; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; BLOOD CELLS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84897140103     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.9     Document Type: Article

References (23)

1. Lai CP-K, Breakefeld XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front. Physio. 3, 228 (2012).
2. Waldenström A, Gennebäck N, Hellman U et al. Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS ONE 7(4), e34653 (2012).
3. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593 (2009).
4. Verderio C, Muzio L, Turola E et al. Myeloid microvesicles are a marker and therapeutic target for neuroinfammation. Ann. Neurol. 72, 610-624 (2012).
5. Pisetsky DS, Ullal AJ, Gauley J et al. Microparticles as mediators and biomarkers of rheumatic disease. Rheumatology (Oxford) 51(10), 1737-1746 (2012).
6. Sellam J, Proulle V, Jüngel A et al. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res. Ther. 11(5), R156 (2009).
7. Sadovnick A. European Charcot Foundation Lecture: the natural history of multiple sclerosis and gender. J. Neurol. Sci. 286(1-2), 1-5 (2009).
8. Roxburgh RH, Seaman SR, Masterman T et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64(7), 1144-1151 (2005).
9. Sheremata WA, Jy W, Delgado S et al. Interferon-beta1a reduces plasma CD31+ endothelial microparticles (CD31 + EMP) in multiple sclerosis. J. Neuroinfammation. 3, 23 (2006).
10. Lowery-Nordberg M, Eaton E, Gonzalez-Toledo E et al. The effects of high dose interferon-p1a on plasma microparticles: correlation with MRI parameters. J. Neuroinfammation. 8, 43 (2011).
11. Sheremata W, Jy W, Horstman L et al. Evidence of platelet activation in multiple sclerosis. J. Neuroinfammation. 5, 27 (2008).
12. Minagar A, Jy W, Jimenez JJ et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 56(10), 1319-1324 (2001).
13. Robert S, Poncelet P, Lacroix R et al. Standardization of platelet derived microparticle counting using calibrated beads and a Cytomics FC500 routine fow cytometer: a frst step towards multicenter studies? J. Thromb. Haemost. 7, 190-197 (2008).
14. Jy W, Minagar A, Jimenez JJ et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Front. Biosci. 9, 3137-3144 (2004).
15. Barry OP, Praticò D, Savani RC et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J. Clin. Invest. 102(1), 136-144 (1998).
16. Andreola G, Rivoltini L, Castelli C et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195(10), 1303-1316 (2002).
17. Sarkar A, Mitra S, Mehta S et al. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS ONE 4(9), e7140 (2009).
18. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 93(1), 1-12 (2011).
19. Planas R, Jelcic I, Schippling S et al. Natalizumab treatment perturbs memory-and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur. J. Immunol. 42(3), 790-798 (2012).
20. Jimenez J, Jy W, Mauro LM et al. Horstman LL. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult. Scler. 11(3), 310-315 (2005).
21. Irizar H, Muñoz-Culla M, Zurriarían O et al. HLA-DRB1*15:01 and multiple sclerosis: a female association? Mult. Scler. 18(5), 569-577 (2012).
22. Madden LA, Vince RV, Sandström ME et al. Microparticle-associated vascular adhesion molecule-1 and tissue factor follow a circadian rhythm in healthy human subjects. Thromb. Haemost. 99(5), 909-915 (2008).
23. Bastos-Amador P, Royo F, Gonzalez E et al. Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability. J. Proteomics. 75(12), 3574-3584 (2012).